logoTry Persana

GTN - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about GTN including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

GTN company logo

Transforming drug discovery through interdisciplinary innovation.

GTN is focused on transforming drug discovery by combining machine learning and quantum physics.

HeadquartersLondon, United Kingdom
Team size1-10
Founded2017

What is GTN? - Company Overview & Details

GTN is GTN is focused on transforming drug discovery by combining machine learning and quantum physics. Founded in 2017, the company is headquartered in London, United Kingdom.

Who Founded GTN?

GTN was founded by Noor Shaker, Vid Stojevic.

Who are the Key Executives at GTN? - Leadership Team

GTN is led by experienced executives in key positions:

Chief Executive Officer (CEO) of GTN

Bill YdeCEO

Chief Technology Officer (CTO) of GTN

CTO

About Bill Yde - CEO of GTN

Bill Yde serves as the Chief Executive Officer of GTN, leading the company's strategic vision and operations.

GTN Company Details & Key Information

Where is GTN located?

GTN is headquartered in London, United Kingdom.

How many employees does GTN have?

GTN has 1-10 employees.

When was GTN founded?

GTN was founded in 2017.

GTN Official Website

How much funding has GTN raised?

GTN has raised $2.78 Million across 1 funding rounds. The most recent funding was completed on 2018-05-10.

Funding Overview

GTN raised £2.1 million ($2.78 million) in a Seed round to enhance their drug discovery technology.

$2.78 Million
Total Funding Raised
1
Funding Rounds
2018-05-10
Latest Round

GTN Funding History

Seed
2018-05-10
$2.78 Million

Who are the key investors in GTN?

GTN is backed by 3 key investors including Octopus Ventures, Pentech, Entrepreneur First. These investors focus on Biotechnology, Pharmaceuticals sectors.

GTN Investor Overview

3
Key Investors
2
Focus Areas
0
Notable Investments

Complete List of GTN Investors

Octopus Ventures

Leading investor in the Seed round.

Investment Focus
Biotechnology
Pharmaceuticals

Pentech

Backed the Seed funding.

Entrepreneur First

Supported the Seed funding for GTN.

What sectors do GTN investors focus on?

The investors backing GTN primarily focus on Biotechnology, Pharmaceuticals sectors.

Biotechnology
Pharmaceuticals

Featured Investor: Octopus Ventures

Octopus Ventures

Leading investor in the Seed round.

Notable Investments:

What are GTN's future plans?

GTN GTN aims to revolutionize drug discovery through continued innovation and interdisciplinary solutions.

GTN Strategic Outlook

Strategic Focus
Defined
2
Key Challenges
2
Growth Opportunities

What challenges does GTN face?

GTN has identified 2 key challenges that need to be addressed for continued growth and success.

Key Challenges for GTN

1

High cost and time of drug development

2

Competition in biotech innovation

What opportunities does GTN have?

GTN has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for GTN

1

Growing demand for novel drugs

2

Potential partnerships with research institutions

GTN Strategic Position Summary

Key Focus Areas

GTN is addressing 2 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about GTN?

GTN has 2 recent news updates covering key business developments and market activities.

GTN News Overview

2
Recent Articles
Active
Media Coverage
2020-10-20
Latest Update

What is GTN in the news for?

GTN is currently featured in news for GTN Ltd hired Bill Yde as CEO on Jan 1st '05. and other significant business developments.

Recent News Articles About GTN

Article 1
2020-10-20

GTN Ltd hired Bill Yde as CEO on Jan 1st '05.

Bill Yde became the CEO of GTN Limited in 2005. This analysis assesses whether his compensation aligns with company performance.

simplywall.st
Read News
Article 2
2018-05-10

GTN Ltd received financing of $2.78M in Seed on May 1st '18.

GTN raised £2.1 million ($2.78 million) in a Seed round, leveraging AI and quantum physics for drug discovery.

shack15.com
Read News

GTN FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about GTN including information about founders, CEO, funding history, investors, headquarters location, and company details. 18 frequently asked questions covering key information about the company.

GTN Questions & Answers - Company Information

Q1

What is GTN?

GTN is focused on transforming drug discovery by combining machine learning and quantum physics.

Q2

Who founded GTN?

GTN was founded by Noor Shaker, Vid Stojevic.

Q3

Who is the CEO of GTN?

The CEO of GTN is Bill Yde.

Q4

How much funding has GTN raised?

GTN has raised a total of $$2.78 Million across 1 funding rounds. The most recent funding was completed on 2018-05-10.

Q5

Who are the investors in GTN?

GTN's key investors include Octopus Ventures, Pentech, Entrepreneur First.

Q6

Where is GTN headquartered?

GTN is headquartered in London, United Kingdom.

Q7

When was GTN founded?

GTN was founded in 2017.

Q8

How many employees does GTN have?

GTN has 1-10 employees.

Q9

What is GTN's official website?

You can visit GTN's official website at http://gtn.ai/.

Q10

What was GTN's latest funding round?

GTN's latest funding round was a Seed round of $$2.78 Million completed on 2018-05-10.

Q11

Who is founder?

Bill Yde

Q12

What does the company do?

GTN is focused on transforming drug discovery by combining machine learning and quantum physics.

Q13

How much funding?

$2.78 Million

Q14

Latest funding date?

2018-05-10

Q15

Who are the investors?

Octopus Ventures Pentech Entrepreneur First

Q16

What are the challenges?

High cost and time of drug development Competition in biotech innovation

Q17

What are the opportunities?

Growing demand for novel drugs Potential partnerships with research institutions

Q18

Latest news?

Bill Yde became the CEO of GTN Limited in 2005. This analysis assesses whether his compensation aligns with company performance. GTN raised £2.1 million ($2.78 million) in a Seed round, leveraging AI and quantum physics for drug discovery.

More Information About GTN

For additional details about GTN, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.